

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re the Application of

Alfredo Nicosia, et al

Application No. 09/463,998

Filed: May 15, 2000

For: MIMOTOPES OF HYPERVARIABLE
REGION 1 OF THE E2 GLYCOPROTEIN
OF HCV AND USES THEREOF



GROUP ART UNIT 1645

11/6/00
RECEIVED
12/1/00
TECH CENTER 1600/2900

Certificate of Mailing Under 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited on December 1, 2000 with the United States Postal Service as first class mail in an envelope addressed to COMMISSIONER OF PATENTS AND TRADEMARKS, Washington, D.C. 20231.

December 1, 2000
Date of Certificate

Jane C. Bogan
Jane C. Bogan

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, applicants hereby submit the attached PTO Form-1449, listing references which the patent examiner is requested to consider and make of record in the above-identified application. Copies of the listed references are enclosed herewith. This submission is believed to be in full compliance with the requirements of 37 C.F.R. §1.98.

In the opinion of the undersigned, the foregoing references are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

It is believed that the subject matter claimed in the present application constitutes a significant advance in the art, as represented by the references discussed above, and is deserving of patent protection. Early and favorable consideration leading to prompt issuance of this application is earnestly solicited.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By Kathleen D. Rigaut
Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100
Facsimile: (215) 563-4044

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
Mewburn 463,098

APPLICATION NO. 09/463,098

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT
ALFREDO NICOSIA, et al.

RECEIVED

DEC 01 2000

(Use several sheets if necessary)


FILING DATE

May 15, 2000

GROUP

1645

TECH CENTER 1600/2900



PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
1A 9 6 4 0 7 6 4	19 Dec. 1996	WO US			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

2A	Peter Jackson, et al. Reactivity of Synthetic Peptides Representing Selected Sections of Hepatitis C Virus Core and Envelope Proteins With a Panel of Hepatitis C Virus-Seropositive Human Plasma. Journal of Medical Virology 51:67-79 (1997); XP-002120165
2B	Andree Zibert, et al. Epitope Mapping of Antibodies Directed against Hypervariable Region 1 in Acute Self-Limiting and Chronic Infections due to Hepatitis C Virus. Journal of Virology, May 1997, p. 4123-4127; XP-002120167
2C	Giulia Puntoriero, et al., Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. The EMBO Journal Vol. 17 No. 13 pp. 3521-3533, 1998; XP-002120168
2D	Nobuyuki Kato, et al., Susceptibility of Human T-Lymphotropic Virus Type I Infected Cell Line MT-2 to Hepatitis C Virus Infection. Biochemical and Biophysical Research Communications. Vol. 206, No. 3, January 26, 1995, Pages 863-869; XP-002120166
2E	Rosalba Tafi, et al. Identification of HCV Core Mimotopes: Improved Methods for the Selection and Use of Disease-Related Phage-Displayed Peptides; Biol. Chem., Vol. 378, pp. 495-502, June 1997; XP-002120164
2F	Abstract: Oba Yoichi, Antigenic Peptide Derived From Hepatitis C Virus and Antibody Testing Agent Using The Same; Publication No. 11124398; Publication Date: 11-05-99; Int. Cl. C07K 14/18 A61K 39/29 C12N 15/02 G01N 33/576 // C07K 16/10 C12P 21/08; Applicant: Japan Energy Corp. Application Number: 09290165; Application Date: 22-10-97.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.